SPECIAL ISSUE GUEST-EDITORS: 

Giulia Treccani, University of Marburg, Germany and Todd Gould, University of Maryland, USA

In recent years, the field of psychopharmacology has witnessed rapid developments, with the potential to fundamentally transform the landscape of treatment options for neuropsychiatric disorders. Among the most notable advancements are for example the emergence of a rapid-acting antidepressant, ketamine, offering new hope that this finding will lead to further discovery and development of new possibilities for patients with depression.

Acta Neuropsychiatrica announces a call for submissions to a special issue titled "Progress in Psychopharmacology," dedicated to showcasing the latest advancements in the field. This issue aims to cover a wide range of topics, from preclinical science to cutting-edge overviews of new drugs in clinical trials and comprehensive pharmacoepidemiological studies, underscoring their significance in the treatment of neuropsychiatric disorders. We invite researchers to contribute original articles and review papers that provide deep insights into both clinical and preclinical studies, with a particular emphasis on novel findings in drug mechanisms of action, development, and treatment outcomes.

Learn more about how to submit here.

Final submissions will be due December 1st 2024. 

All submissions will be peer-reviewed.